Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia.
cerebellum
frataxin
gene therapy
glutamatergic and GABAergic synapses
mitochondria dynamics
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
11
2021
accepted:
28
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by deficiency of the mitochondrial protein frataxin. Lack of frataxin causes neuronal loss in various areas of the CNS and PNS. In particular, cerebellar neuropathology in FRDA patients includes loss of large principal neurons and synaptic terminals in the dentate nucleus (DN), and previous studies have demonstrated early synaptic deficits in the Knockin-Knockout mouse model of FRDA. However, the exact correlation of frataxin deficiency with cerebellar neuropathology remains unclear. Here we report that doxycycline-induced frataxin knockdown in a mouse model of FRDA (FRDAkd) leads to synaptic cerebellar degeneration that can be partially reversed by AAV8-mediated frataxin restoration. Loss of cerebellar Purkinje neurons and large DN principal neurons are observed in the FRDAkd mouse cerebellum. Levels of the climbing fiber-specific glutamatergic synaptic marker VGLUT2 decline starting at 4 weeks after dox induction, whereas levels of the parallel fiber-specific synaptic marker VGLUT1 are reduced by 18-weeks. These findings suggest initial selective degeneration of climbing fiber synapses followed by loss of parallel fiber synapses. The GABAergic synaptic marker GAD65 progressively declined during dox induction in FRDAkd mice, while GAD67 levels remained unaltered, suggesting specific roles for frataxin in maintaining cerebellar synaptic integrity and function during adulthood. Expression of frataxin following AAV8-mediated gene transfer partially restored VGLUT1/2 levels. Taken together, our findings show that frataxin knockdown leads to cerebellar degeneration in the FRDAkd mouse model, suggesting that frataxin helps maintain cerebellar structure and function.
Identifiants
pubmed: 35401081
doi: 10.3389/fnins.2022.819569
pmc: PMC8987918
doi:
Types de publication
Journal Article
Langues
eng
Pagination
819569Informations de copyright
Copyright © 2022 Mercado-Ayón, Warren, Halawani, Rodden, Ngaba, Dong, Chang, Fonck, Mavilio, Lynch and Lin.
Déclaration de conflit d'intérêts
FM, CF, and JC were employees of Audentes/Astellas at the time the work was performed. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Chem Biol. 2006 Oct;2(10):551-8
pubmed: 16921367
Elife. 2017 Dec 19;6:
pubmed: 29257745
J Neurol. 2013 Sep;260(9):2362-9
pubmed: 23775342
Ann Clin Transl Neurol. 2020 Jan;7(1):94-104
pubmed: 31854120
Pharmacol Res Perspect. 2021 May;9(3):e00755
pubmed: 33951329
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12239-43
pubmed: 11035806
J Biomol Tech. 2007 Apr;18(2):120-3
pubmed: 17496224
Hum Brain Mapp. 2021 Nov;42(16):5334-5344
pubmed: 34523778
Acta Neuropathol. 2011 Sep;122(3):323-30
pubmed: 21638087
Dis Model Mech. 2012 Nov;5(6):860-9
pubmed: 22736457
Mol Ther Methods Clin Dev. 2020 Sep 01;19:120-138
pubmed: 33209958
Int J Mol Sci. 2018 May 17;19(5):
pubmed: 29772845
Neurology. 2019 Jul 9;93(2):e116-e124
pubmed: 31197032
J Am Assoc Lab Anim Sci. 2016;55(4):467-74
pubmed: 27423155
Hum Mol Genet. 2005 Dec 1;14(23):3643-59
pubmed: 16236762
Neurobiol Dis. 2014 Mar;63:129-40
pubmed: 24326163
Eye (Lond). 2012 Feb;26(2):315-20
pubmed: 22094302
Hum Gene Ther. 2020 Dec;31(23-24):1226-1236
pubmed: 33238751
Hum Mol Genet. 2019 Apr 15;28(8):1274-1285
pubmed: 30544254
Front Oncol. 2018 Oct 12;8:452
pubmed: 30364293
Dis Model Mech. 2017 Dec 19;10(12):1529-1538
pubmed: 29259026
Mol Ther. 2018 Aug 1;26(8):1940-1952
pubmed: 29853274
Transgenic Res. 2012 Oct;21(5):1099-107
pubmed: 22167485
Science. 1996 Mar 8;271(5254):1423-7
pubmed: 8596916
PLoS One. 2013 May 31;8(5):e64561
pubmed: 23741339
Biochemistry. 2010 Nov 2;49(43):9132-9
pubmed: 20873749
Nat Med. 2014 May;20(5):542-7
pubmed: 24705334
J Child Neurol. 2012 Sep;27(9):1223-9
pubmed: 22832776
Neurol Genet. 2018 Jul 23;4(4):e250
pubmed: 30065952
Genomics. 2006 Nov;88(5):580-90
pubmed: 16919418
Brain. 2019 Jun 1;142(6):e23
pubmed: 31081508
Acta Neuropathol Commun. 2016 May 23;4(1):53
pubmed: 27215193
Dis Model Mech. 2018 Jan 29;11(1):
pubmed: 29419392
J Neurosci. 2004 Feb 25;24(8):1987-95
pubmed: 14985441
Hum Mol Genet. 2017 Jul 15;26(14):2627-2633
pubmed: 28444186
Mol Ther. 2007 Jun;15(6):1072-8
pubmed: 17375064
Genomics. 2004 Aug;84(2):301-10
pubmed: 15233994